FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 345:375-376 August 2, 2001 Number 5 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

To the Editor: Musselman et al. (March 29 issue)¹ suggest that prophylactic treatment with paroxetine is an effective strategy for minimizing depression induced by treatment with interferon alfa in patients with malignant melanoma. However, this strategy would require unnecessary antidepressant therapy in a large number of patients.

We have prospectively monitored patients with chronic hepatitis C during therapy with interferon alfa-2b (3 million to 5 million IU given three times a week), using repeated psychometric testing and psychological interviews to assess the psychiatric side effects of interferon alfa-2b. Clinically evident depression (according to the criteria of the International Classification of . . . [Full Text of this Article]

References

This article has been cited by other articles:

• Kraus, M R, Schafer, A, Schottker, K, Keicher, C, Weissbrich, B, Hofbauer, I, Scheurlen, M (2008). Therapy of interferon-induced depression in chronic hepatitis C with citalopram: a randomised, double-blind, placebo-controlled study. Gut 57: 531-536 [Abstract] [Full Text]  
• Gochee, P. A., Powell, E. E., Purdie, D. M., Pandeya, N., Kelemen, L., Shorthouse, C., Jonsson, J. R., Kelly, B. (2004). Association Between Apolipoprotein E {epsilon}4 and Neuropsychiatric Symptoms During Interferon {alpha} Treatment for Chronic Hepatitis C. Psychosomatics 45: 49-57 [Abstract] [Full Text]